The Center for Applied Science and Technology provides the infrastructure and resources needed to facilitate scientific discovery and incorporate emerging technologies and new testing modalities into clinical diagnostics for improved patient care and outcomes.

By supporting the broad range of research being conducted throughout the MaineHealth Institute for Research including the Center for Molecular Medicine, the Center for Interdisciplinary Population Health Research, the Center for Clinical and Translational Science, the Clinical Trials Office, and the Northern New England Clinical and Translational Research Network, the Center will help move MaineHealth forward as an academic medical center. The Center enables NorDx to develop and validate new testing modalities within a research regulatory framework that meet evolving Precision Medicine guidelines and allows the incorporation of emerging technologies into clinical diagnostics for improved patient care and outcomes. NorDx resources and services available to investigators through the Center include a research service unit for efficient startup of sponsored and non-sponsored research studies, phlebotomy services, sample transport services, collection of samples of research value in real time, biomarker testing on high throughput instrumentation in a CLIA/CAP accredited laboratory and genomic testing capabilities.

See below for an outline of the Center’s non-clinical and clinical trials supported initiatives:

A Period Seroprevalence (SARS-CoV2) Survey in MHCCN Cancer Healthcare Workers (HCWs) Providing Patient Care during the Height of the Outbreak: A Registry Study.
Principal Investigator: Scot, Remick, MD (Medical Oncology).
Study Support: Sample processing, deidentifcation and storage from more than 450 study participants

Cardio Surveillance of MHCCN Cancer Patients Undergoing Immune Checkpoint Blockade
Principal Investigator: Sanjeev Francis, MD, MH Cardiology Specialist
Study Support: Phlebotomy, sample processing, deidentification, storage and immunoassay testing for 3 or more biomarkers; enrollment goal is 25 participants with 6 visits per participant (150 samples)

RECOVER: Researching COVID to Enhance Recovery
Principal Investigator: Cliff Rosen, MD, Faculty Scientist III, MHIR
Study Support: Sample processing, deidentification, storage and shipment from more than ? study participants

National COVID Cohort Collaborative (N3C)
Principal Investigator: Susan Santangelo, ScD, Director, Center for Clinical and Translational Science, MHIR
Study Support: Extraction of COVID RNA from Nasal Swabs, deidentification and shipment to JAX for sequencing; 150 samples shipped every 2 weeks (total as of 8/11/22 is 556)

Beta1-Selective Blockade for Prevention of Post-Menopausal Bone Loss: A Phase 3, Multi-Center, Doubleblinded, Randomized, Placebo Controlled Trial. (APO)
Principal Investigators: Cliff, Rosen, MD, Faculty Scientist III, MHIR  and Irwin Brodsky, MD, MMP Endocrinology and Diabetes.
Study Support: Sample processing and shipment of 695 samples over 5 years

SARS-CoV2 Antibody Response and Detection
Principal Investigators: Doug Sawyer, MD, PhD, MH Chief Academic Officer and Josh Boucher, PhD, IDEXX Laboratories
Study Support: Collection, processing, transport and storage of NP or MT swabs, saliva and blood samples and SARS-CoV-2 antibody testing

The Role of BMP9/BMP10/ALK1 signaling in patients with heart failure after continuous left ventricle assist device implantation with arteriovenous malformations
Principal Investigator: Esther Shao, MD, MH Cardiology
Study Support: Phlebotomy services, sample processing, deidentifiation and storage

Genetic Factors of Non-Diabetic Chronic Kidney Disease (CKD) in Maine
Principal Investigator, Benjamin King, PhD, Associate Professor, University of Maine
Start Date: TBD
Study Support: Study team coordination, IRB submission assistance, patient consent, sample collection, processing, storage and shipment for 40 study participants

Immulina as an Antiviral Immune Modulator for Patients with PASC and Persistent Inflammation
Principal Investigator: Cliff Rosen, MD, Faculty Scientist III, MHIR
Start Date: TBD
Study Support: Sample processing, deidentification, storage and shipment

Pathobiology in Recover of Metabolic and Immune Systems (PROMIS)
Principal Investigator: Cliff Rosen, MD, Faculty Scientist III, MHIR
Enrollment Goal: 60 participants; two timepoints
Start Date: TBD
Study Support: Sample processing, deidentification, storage and shipment and Immunoassay testing of 120 samples for 11 biomarkers

Clinical course of children with high agricultural PFAS exposures
Principal Investigator: Abby Fleisch, MD, MPH, MMP Pediatric Endocrinology, MHIR Faculty Scientists, CIPHR
Study Support; Phlebotomy, sample processing, deidentification storage and shipping for 15 study participants

Human Epilepsy Project 3: Newly Diagnosed Idiopathic Generalized Epilepsy (HEP3)
Principal Investigator: Heidi Henninger, MD
Enrollment: 20 participants with 3 time points each (60 samples)

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of JNJ-40411813 as Adjunctive Therapy in Subjects with Focal Onset Seizures with Suboptimal Response to Levetiracetam (EPY)
Principal Investigator: Heidi Henninger, MD, MH Neurology

A Phase IIIB Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults with Relapsing Multiple Sclerosis Musette (BN42082)
Principal Investigator: Biljana Beretich, MD, MH Neurology

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Trial of  CVL-865 as Adjunctive Therapy in Adults with Drug-Resistant Focal Onset Seizures (REALIZE)
Principal Investigator: Heidi Henninger, MD, MH Neurology

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses of Tavapadon in Early Parkinson’s Disease (TemPo -1 Trial)
Principal Investigator: Michael Kleinman, MD, MH Neurology

58 Week Open label trial of Tavapadon in Parkinson’s Disease (TemPo 4)
Principal Investigator: Michael Kleinman, MD, MH Neurology

Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer’s Disease (TRAILBLAZER-ALZ2)
Principal Investigator: Eric Dinnerstein, MD, MH Neurology

A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 as Adjunctive Therapy in Focal-onset Epilepsy (XPF-008-201) (XENON)
Principal Investigator: Heidi Henninger, MD, MH Neurology

Center for Applied Science & Technolgy
81 Research Drive
Scarborough, Maine 04074

Contact Us